23.47
+1.13(+5.06%)
Currency In USD
| Previous Close | 22.34 |
| Open | 22.33 |
| Day High | 23.48 |
| Day Low | 22.13 |
| 52-Week High | 51.61 |
| 52-Week Low | 18.53 |
| Volume | 587,977 |
| Average Volume | 952,004 |
| Market Cap | 1.5B |
| PE | -8.53 |
| EPS | -2.75 |
| Moving Average 50 Days | 26.07 |
| Moving Average 200 Days | 36.91 |
| Change | 1.13 |
If you invested $1000 in Vera Therapeutics, Inc. (VERA) since IPO date, it would be worth $2,040.87 as of April 25, 2025 at a share price of $23.47. Whereas If you bought $1000 worth of Vera Therapeutics, Inc. (VERA) shares 3 years ago, it would be worth $1,108.12 as of April 25, 2025 at a share price of $23.47.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
GlobeNewswire Inc.
Apr 03, 2025 12:00 PM GMT
On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA),
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 27, 2025 1:00 PM GMT
BRISBANE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dise
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
GlobeNewswire Inc.
Jan 13, 2025 12:00 PM GMT
BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dise